STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRNA
  4. [Form 4] Moderna, Inc. Insider Trading Activity

Tax-driven stock sale by Moderna (MRNA) director after RSU vesting

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Moderna, Inc. director Hussain Abbas reported an exercise of restricted stock units (RSUs) and a related share sale. On April 30, 2026, RSUs covering 16,233 shares converted into common stock on a one-for-one basis when they vested in full. On May 1, 2026, Abbas sold 5,682 common shares at an average price of $46.63 per share under a pre-arranged Rule 10b5-1 trading plan to generate cash to cover tax liabilities from the RSU vesting. After these transactions, he directly owned 12,066 Moderna common shares.

Positive

  • None.

Negative

  • None.
Insider Hussain Abbas
Role null
Sold 5,682 shs ($265K)
Type Security Shares Price Value
Sale Common Stock 5,682 $46.63 $265K
Exercise Restricted Stock Units 16,233 $0.00 --
Exercise Common Stock 16,233 $0.00 --
Holdings After Transaction: Common Stock — 12,066 shares (Direct, null); Restricted Stock Units — 0 shares (Direct, null)
Footnotes (1)
  1. Restricted stock units convert into common stock on a one-for-one basis. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares subject to this restricted stock unit award vested in full on April 30, 2026.
Shares sold 5,682 shares Open-market sale on May 1, 2026
Sale price per share $46.63 per share Average price for 5,682 shares sold
RSUs converted 16,233 shares Restricted stock units converting to common stock on April 30, 2026
Post-transaction holdings 12,066 shares Common shares owned directly after reported transactions
Exercise transactions 1 exercise, 16,233 shares Derivative exercise/conversion activity summarized in filing
Restricted Stock Units financial
"The shares subject to this restricted stock unit award vested in full on April 30, 2026."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 10b5-1 trading plan regulatory
"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hussain Abbas
(Last)(First)(Middle)
C/O MODERNA, INC.
325 BINNEY STREET
(Street)
CAMBRIDGE MASSACHUSETTS 02142
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/30/2026M(1)16,233A(1)17,748D
Common Stock05/01/2026S(2)5,682D$46.6312,066D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)04/30/2026M(1)16,233 (3) (3)Common Stock16,233$00D
Explanation of Responses:
1. Restricted stock units convert into common stock on a one-for-one basis.
2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.
3. The shares subject to this restricted stock unit award vested in full on April 30, 2026.
/s/ James Dillon, As Attorney-in-Fact05/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Moderna (MRNA) director Hussain Abbas report?

Director Hussain Abbas reported exercising restricted stock units into 16,233 common shares on April 30, 2026, then selling 5,682 shares at $46.63 on May 1, 2026 under a Rule 10b5-1 trading plan to cover tax liabilities.

How many Moderna (MRNA) shares did Hussain Abbas sell and at what price?

Hussain Abbas sold 5,682 Moderna common shares at an average price of $46.63 per share. The sale occurred on May 1, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan to generate proceeds for tax obligations.

What RSU activity did Moderna (MRNA) disclose for director Hussain Abbas?

Abbas had 16,233 restricted stock units convert into 16,233 common shares on April 30, 2026. The filing notes that these RSUs vested in full on that date and convert into common stock on a one-for-one basis.

How many Moderna (MRNA) shares does Hussain Abbas hold after these transactions?

Following the RSU conversion and subsequent sale, Hussain Abbas directly owned 12,066 Moderna common shares. This figure reflects his post-transaction holdings reported in the Form 4 after selling 5,682 shares and receiving 16,233 shares from the RSU vesting.

Was the Moderna (MRNA) director’s share sale discretionary or pre-planned?

The filing states the 5,682-share sale was executed under a Rule 10b5-1 trading plan adopted on September 5, 2025. It also explains that the sale was made to generate proceeds to cover tax liabilities from the vesting of restricted stock units.